entertainment -WSS

entertainment

author：hotspot 2025-10-03 00:06:44 - browse：3

Layoff concept illustration of empty desks and people walking away. — Adobe

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and acknowledged that a pair of collaboration deals with pharma companies had fallen apart.

The downsizing is temporary, CEO Ameet Nathwani told STAT. The company needed to hire new employees with expertise to help move the company’s first drugs into clinical trials and expand its AI capabilities. And with funding for early-stage biotechs still sparse, leadership opted to cut some positions and use the savings to fill new ones over the coming months. Roughly 20 positions were cut.

“We talked to investors right now [about raising more money], and they think that the environment for a preclinical company — it’s not even worth having that discussion,” Nathwani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare drug price negotiation hearing pits pharma v Biden admin

WSS

Longer MASH drug regimen improved liver, Akero study finds

Testing GLP

Mirador, a new biotech startup, launches with $400 million

Florida health officials providing scant details on measles cases

Readout Newsletter: Illumina, CRISPR, Regeneron

Microsoft's Peter Lee: Generative AI could help doctors be more human

explore

entertainment

hotspot

Affirmative action in medical school literally saved lives

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medical records are filled with copy

Lack of health data on LGBTQ+ people has serious consequences

Bright Health sells Medicare Advantage business to Molina

Pregnant women don't need prenatal multivitamins, study concludes

Alkermes shareholders re

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

focus

CRISPR technology availability, affordability needs to be expanded

He's 19 months old and has one of the world’s rarest diseases

Streamlined flu vaccines recommended by FDA advisory panel

Medicare drug price negotiation continues, as pharma counteroffers

The public health thinking behind the CDC’s new Covid guidance

Longer MASH drug regimen improved liver, Akero study finds

focus

leisure time

leisure time

knowledge